CA2341525A1 - Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands - Google Patents

Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands Download PDF

Info

Publication number
CA2341525A1
CA2341525A1 CA002341525A CA2341525A CA2341525A1 CA 2341525 A1 CA2341525 A1 CA 2341525A1 CA 002341525 A CA002341525 A CA 002341525A CA 2341525 A CA2341525 A CA 2341525A CA 2341525 A1 CA2341525 A1 CA 2341525A1
Authority
CA
Canada
Prior art keywords
mhz
propylamine
nmr
disorders
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341525A
Other languages
English (en)
French (fr)
Inventor
David Reginald Adams
Jonathan Mark Bentley
Jonathan Richard Anthony Roffey
Richard John Hamlyn
Suneel Gaur
Matthew Alexander James Duncton
David Bebbington
Nathaniel Julius Monck
Claire Elizabeth Dawson
Robert Mark Pratt
Ashley Roger George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341525A1 publication Critical patent/CA2341525A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CA002341525A 1998-09-01 1999-09-01 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands Abandoned CA2341525A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9819033.3 1998-09-01
GBGB9819033.3A GB9819033D0 (en) 1998-09-01 1998-09-01 Chemical compounds VI
PCT/GB1999/002879 WO2000012475A1 (en) 1998-09-01 1999-09-01 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands

Publications (1)

Publication Number Publication Date
CA2341525A1 true CA2341525A1 (en) 2000-03-09

Family

ID=10838165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341525A Abandoned CA2341525A1 (en) 1998-09-01 1999-09-01 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands

Country Status (7)

Country Link
US (1) US6380238B1 (https=)
EP (1) EP1109784A1 (https=)
JP (1) JP2002523491A (https=)
AU (1) AU5637199A (https=)
CA (1) CA2341525A1 (https=)
GB (1) GB9819033D0 (https=)
WO (1) WO2000012475A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
WO2001040183A1 (en) * 1999-12-03 2001-06-07 Alcon Universal Ltd. 1-aminoalkyl-1h-indoles for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
BR0109193A (pt) * 2000-03-17 2003-05-27 Alcon Inc Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
IL155875A0 (en) 2000-11-20 2003-12-23 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
HUP0303316A2 (hu) 2000-12-20 2004-01-28 Bristol-Myers Squibb Pharma Company Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
JP2004532887A (ja) 2001-06-01 2004-10-28 アルコン,インコーポレイテッド 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
CA2447480A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
JP2004534781A (ja) 2001-06-01 2004-11-18 アルコン,インコーポレイテッド 新規なアリールアミノプロパン類似体および緑内障治療へのこれらの使用
US6884816B2 (en) 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
CN100484933C (zh) 2002-06-19 2009-05-06 比奥维特罗姆股份公开公司 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途
JP2006501245A (ja) * 2002-08-30 2006-01-12 アルコン,インコーポレイテッド 置換された5−クロマン−5−イル−エチルアミン化合物および緑内障の治療のためのその使用
US7795280B2 (en) 2002-11-07 2010-09-14 N.V. Organon Indoles useful in the treatment of androgen-receptor related diseases
BR0316775A (pt) 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
TW200520760A (en) 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
CN101151249B (zh) * 2005-03-31 2011-04-06 辉瑞产品公司 环戊吡啶及四氢喹啉衍生物
AP2007004144A0 (en) * 2005-03-31 2007-08-31 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
AU2007274710A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine
GB0715047D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel Compounds
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN109071435A (zh) * 2016-01-21 2018-12-21 耶路撒冷希伯来大学伊森姆研究发展公司 吲哚啉衍生物、包含它们的组合物及其用途
WO2018009854A1 (en) * 2016-07-08 2018-01-11 Arizona Board Of Regents On Behalf Of The University Of Arizona Indoline derivatives and method for using and producing the same
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
AU2020228289B2 (en) * 2019-02-27 2026-02-05 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
KR20230066543A (ko) * 2020-06-10 2023-05-16 델릭스 테라퓨틱스, 인크. 이소트립타민 사이코플라스토겐 및 이의 용도
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
KR20250034020A (ko) * 2022-04-19 2025-03-10 마인드셋 파마 인크. 세로토닌 관련 장애를 치료하는 데 유용한 세로토닌성 제제로서의 인돌린 유도체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270114B (https=) * 1993-10-22 1996-02-11 Hoffmann La Roche
JPH10500960A (ja) * 1994-05-28 1998-01-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1d−アンタゴニスト活性を有するアミド誘導体
FR2742047B1 (fr) * 1995-12-06 1998-01-16 Oreal Compositions de teinture des fibres keratiniques contenant des derives n-substitues de la 4-hydroxy indoline, nouveaux derives, leur procede de synthese, leur utilisation pour la teinture, et procede de teinture

Also Published As

Publication number Publication date
EP1109784A1 (en) 2001-06-27
WO2000012475A1 (en) 2000-03-09
GB9819033D0 (en) 1998-10-28
JP2002523491A (ja) 2002-07-30
US6380238B1 (en) 2002-04-30
AU5637199A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
US6380238B1 (en) Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands
US8912220B2 (en) Compounds and methods of use thereof
EP1202965B1 (en) Indole derivatives, processes for their preparation, pharmaceutical compositions containing them and their medicinal application
US5030643A (en) Heterocyclic amide derivatives and use
US5637593A (en) Tryptamine analogues as 5-ht1-like agonists
EP1328515B1 (en) Indoline derivatives and their use as 5-ht2 receptor ligands
JP3224372B2 (ja) 複素環式カルボキサミド
EP1109809B1 (en) Pyrroloquinolines for treatment of obesity
CA2399111A1 (en) New aza-indolyl derivatives
CA2359034A1 (en) Pyrazino(aza)indole derivatives
NO321527B1 (no) Pyrroloindoler, pyridoindoler og azepinoindol-derivater, anvendelse av disse ved fremstilling av et medikament, farmasoytisk preparat omfattende slike og fremgangsmate for fremstilling av preparatet.
US20070099980A1 (en) Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
US6391891B1 (en) Bicyclic compounds as ligands for 5-HT1 receptors
EP1129078B1 (en) Indazole derivatives with 5-ht2 receptor activity
WO2000012482A2 (en) Indazole derivatives with 5-ht2 receptor activity
IE60480B1 (en) Carboxamide derivatives
WO2000017170A2 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead